Integra LifeSciences (IART) Stock Forecast & Price Target

$24.41 -0.17 (-0.69%)

(As of 11:51 AM ET)

Integra LifeSciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 8 Analyst Ratings

Sell
3

Hold
4

Buy
1

Based on 8 Wall Street analysts who have issued ratings for Integra LifeSciences in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 3 have given a sell rating, 4 have given a hold rating, and 1 has given a buy rating for IART.

Consensus Price Target

$23.00
-5.78% Downside

According to the 8 analysts' twelve-month price targets for Integra LifeSciences, the average price target is $23.00. The highest price target for IART is $35.00, while the lowest price target for IART is $18.00. The average price target represents a forecasted downside of -5.78% from the current price of $24.41.

Get the Latest News and Ratings for IART and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Integra LifeSciences and its competitors.

IART Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	4 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$23.00	$26.50	$28.63	$45.63
Forecasted Upside	-5.78% Downside	37.45% Upside	48.09% Upside	12.99% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

Is the Trump/Musk duo good for shares of TSLA? (Ad)

If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.

Discover how to trade Tesla, simply follow this link here.

IART Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IART Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Integra LifeSciences Stock vs. The Competition

Type	Integra LifeSciences	Medical Companies	S&P 500
Consensus Rating Score	1.75	2.81	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-6.43% Downside	25,943.23% Upside	6.72% Upside
News Sentiment Rating	Very Positive News See Recent IART News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/2/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Underweight	$25.00 ➝ $20.00	-18.63%
11/5/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Sell	$16.00 ➝ $22.00	-9.84%
10/14/2024	Truist Financial 2 of 5 stars		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+10.64%
10/7/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underperform ➝ Underperform	$26.00 ➝ $18.00	+4.23%
10/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Zimmerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral
7/30/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$40.00 ➝ $35.00	+37.09%
Get the Latest News and Ratings for IART and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.
5/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
5/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$45.00 ➝ $25.00	+8.04%
11/14/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+36.61%
7/12/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00 ➝ $53.00	+28.33%
6/26/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$55.00 ➝ $44.00	+11.25%
6/8/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
5/24/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$56.00 ➝ $43.00	+6.23%
5/23/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:25 PM ET.

IART Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Integra LifeSciences is $23.00, with a high forecast of $35.00 and a low forecast of $18.00.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" IART shares.
: According to analysts, Integra LifeSciences's stock has a predicted downside of -5.78% based on their 12-month stock forecasts.
: Over the previous 90 days, Integra LifeSciences's stock had 1 upgrade by analysts.
: Integra LifeSciences has been rated by research analysts at Bank of America, BTIG Research, Citigroup, Morgan Stanley, and Truist Financial in the past 90 days.
: Analysts like Integra LifeSciences less than other "medical" companies. The consensus rating for Integra LifeSciences is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IART compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:IART) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Stock Forecast & Price Target